Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Lobe Sciences Ltd. C.LOBE

Alternate Symbol(s):  LOBEF

Healthcare Drug Manufacturers - Major
Lobe Sciences is a leading “BioPsychedelic” company entering clinical stage development focused on transforming psychedelic medicine to benefit patients of all ages. We are engaged in research and development using psychedelic and non-psychedelic compounds targeting the 5HT2 receptor family. Our team is made up of biotech executives who collectively have managed the development and regulatory approval of revolutionary drugs around the globe.


CSE:LOBE - Post by User

Lobe Sciences Ltd. > NEWS: Roadmap for Remainder of 2022 & Early 2023 𓋼𓋺𓋼
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(15)
•••
Comment by fTrudeauon Jun 15, 2022 4:46pm
99 Views
Post# 34759443

RE:NEWS: Roadmap for Remainder of 2022 & Early 2023 𓋼𓋺𓋼

RE:NEWS: Roadmap for Remainder of 2022 & Early 2023 𓋼𓋺𓋼
i read the news release. Doesn't mention much about 2023 but this company definitely has major potential... I wonder how FDA meeting will be in 3rd Q of 2022. They did a share split recently which is beneficial as to not worry about this occuring again. I dig how to the CEO stated he wants to keep shareholders updated.... Many out there do not outright say this. Added to watch list.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities